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ABSTRACT
There are numerous human diseases that are associated with protein
misfolding and the formation of toxic protein aggregates. Activating
the heat shock response (HSR) – and thus generally restoring the
disturbed protein homeostasis associated with such diseases – has
often been suggested as a therapeutic strategy. However, most data
on activating the HSR or its downstream targets in mouse models of
diseases associated with aggregate formation have been rather
disappointing. The human chaperonome consists of many more heat
shock proteins (HSPs) that are not regulated by the HSR, however,
and researchers are now focusing on these as potential therapeutic
targets. In this Review, we summarize the existing literature on a set
of aggregation diseases and propose that each of them can be
characterized or ‘barcoded’ by a different set of HSPs that can rescue
specific types of aggregation. Some of these ‘non-canonical’ HSPs
have demonstrated effectiveness in vivo, in mouse models of protein-
aggregation disease. Interestingly, several of these HSPs also cause
diseases when mutated – so-called chaperonopathies – which are
also discussed in this Review.
KEY WORDS: Chaperonopathies, Heat shock protein, Protein-
aggregation diseases
Introduction
Many heat shock protein (HSP) family members are known to
function as molecular chaperones, meaning that they stabilize and
assist in the correct folding of nascent polypeptides (Ellis and Hartl,
1999). In addition to their role in de novo protein folding, HSPs are
involved in various aspects of proteome maintenance, including
macromolecular-complex assembly, protein transport and
degradation, as well as aggregate dissociation and refolding of
stress-denatured proteins. Under normal cellular conditions, HSP
levels match the overall level of protein synthesis. Under conditions
of stress, mature proteins unfold and exceed the capacity of
chaperone systems to prevent aggregation. Such acute proteotoxic
stress induces a regulated response resulting in increased expression
of some HSPs, which helps to rebalance protein homeostasis.
The human genome encodes more than 100 different HSPs, which
are grouped into seven different families: HSPH (Hsp110), HSPC
(Hsp90), HSPA (Hsp70), DNAJ (Hsp40), HSPB [small Hsp (sHsp)],
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the human chaperonins HSPD/E (HSP60/HSP10) and CCT (TRiC),
plus several regulatory co-factors (Kampinga et al., 2009). In terms
of their regulation, the HSP family members can also be categorized
into three groups: (1) constitutively expressed, but not induced by
stress; (2) constitutively expressed and induced upon stress; and (3)
induced only upon stress (Morimoto, 2008). In addition to their
differential regulation, the various HSPs also show a large degree of
functional diversity with respect to client specificity and client
processing (Kampinga and Craig, 2010). These functional
differences could be very important when investigating their
potential relevance for diseases in which cells are chronically
exposed to proteins that are prone to form toxic protein aggregates.
Examples of such diseases are polyglutamine (polyQ) diseases,
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and
Alzheimer’s disease (AD). This Review discusses how these
diseases can be labeled or ‘barcoded’ by specific sets of HSPs that
can rescue their disease-specific aggregations.
The cellular functions of HSPs
HSPs and de novo protein folding
The general organization of co-translational folding is highly
conserved throughout evolution. Ribosome-binding chaperones (e.g.
specialized Hsp70/HSPAs) first interact with the nascent
polypeptide, followed by a second set of HSPs that do not have a
direct affinity for the ribosome (the classical Hsp70/HSPA system).
The Hsp70/HSPA family is the central component of the cellular
network of molecular chaperones and folding catalysts (Fig. 1A).
Hsp70/HSPA proteins are involved in a wide range of protein quality
control (PQC) functions, including de novo protein folding,
refolding of stress-denatured proteins, protein transport, membrane
translocation and protein degradation. Hsp70/HSPAs never function
alone; they require Hsp40/DNAJ proteins and nucleotide-exchange
factors (NEFs) as partners. DNAJ proteins bind and deliver client
proteins to the Hsp70/HSPA system, upon which the client protein
and DNAJ function together to stimulate HSPA to hydrolyze ATP,
leading to high substrate affinity of HSPA. Following ATP
hydrolysis, NEFs such as BAG-1, HSPBP1 and HSPH bind HSPA
and induce ADP-ATP exchange, leading to substrate release. DNAJs
thus mainly confer client specificity to the Hsp70/HSPA machine,
but can also affect the fate of HSPA clients, whereas NEFs seem to
be mainly involved in client fate (Bukau et al., 2000; Kampinga and
Craig, 2010; Young, 2014) (Fig. 1A). The DNAJ/HSPA system
might also receive clients from small Hsp/HSPB proteins. HSPB
chaperone activity does not need ATP. However, direct interaction
with ATP-dependent chaperones such as HSPA promotes the release
of the bound substrate and subsequent refolding (Boncoraglio et al.,
2012; Garrido et al., 2012).
Proteins that cannot be completely folded by Hsp70/HSPA
machines are transferred to, or handled independently by, the
chaperonins or the Hsp90/HSPC system (Buchner, 1999; Yam et
al., 2008) (Fig. 1A). Substrate transfer to Hsp90/HSPC protein is
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mediated by the HSP-organizing protein (HOP), which uses
multiple tetratricopeptide-repeat domains to form a bridge between
HSPA and HSPC (Buchner, 1999; Young et al., 2001). The
mechanism of handover from Hsp70 to chaperonins remains
unclear in mammals; however, work in the prokaryotic system has
begun to reveal some interesting possibilities. For example, it has
recently been shown that the Hsp70 homolog DnaK binds the M
domain of ClpB to recruit DnaK-bound substrates to the
chaperonin (Seyffer et al., 2012).
HSPs and acute proteotoxic-stress conditions
Cells are constantly challenged by changes in their environment.
Acute stress conditions such as heat shock cause many proteins to
become unfolded. The accumulation of stress-denatured proteins
increases the risk of aggregate formation. In addition to their role
in co-translational folding, the constitutively expressed HSP
members might also assist in aggregate protection and refolding of
stress-unfolded proteins (Fig. 1A). However, it has been shown in
yeast that the stress-inducible cytosolic members of the families,
which are strongly upregulated by the transcription factor heat
shock factor-1 (HSF-1), become more important under such
conditions (Albanèse et al., 2006). Next to this transcriptional
response, HSPB proteins represent an even more rapid response to
environmental stresses (Fig. 1A). Several HSPB members are
rapidly and transiently phosphorylated, whereby their oligomeric
state is dynamically altered and their protective activities are
activated. These protective activities include prevention of
cytoskeletal collapse and chaperoning of soluble proteins, which
can enhance protein refolding or support client degradation
(Garrido et al., 2012).
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Fig. 1. Model of actions and interactions of the HSP
network required for normal protein folding and
refolding upon acute stress or during chronic stress.
HSP families constitute a large group of chaperones that
interact with non-native proteins, assisting their correct
protein folding. HSPs are constitutively expressed, but
their expression levels can increase under conditions of
stress. They are mainly divided into groups:
sHsp/HSPBs, Hsp70/HSPAs, Hsp90/HSPCs and
members of the chaperonin (CCT-Hsp60) family (see
main text for details). (A) During de novo protein folding
and for the refolding of acute-stress-denatured unfolded
proteins, the functional cooperation of different HSPs is
primarily aimed at the structural stabilization of native
proteins for (re)folding. However, in case of failure of
protein folding, HSPs can also assist client degradation
through the ubiquitin-proteasome system (UPS) or the
autophagy-lysosome pathway. The central component of
the chaperone network and folding catalysts is the
Hsp70/HSPA family. Hsp40/DNAJs hydrolyze ATP
(bound to Hsp70/HSPA) to ADP, increasing the affinity of
its substrate-binding domain for unfolded proteins.
Nucleotide-exchange factor (NEF) proteins remove ADP
and substitute ATP, reducing Hsp70/HSPA′s substrate-
binding affinity, allowing release of the folded protein.
Proteins that are unable to utilize Hsp70/HSPAs for
complete folding are transferred to the chaperonin or the
Hsp90/HSPC system. For transfer of substrates from
Hsp70/HSPA to Hsp90/HSPC, HOP is required as a co-
chaperone. Under acute stress conditions, HSPB
oligomers dissociate into dimers to bind unfolded
substrates, thereby avoiding irreversible aggregation of
client proteins. This process allows ATP-dependent
chaperones to assist in the substrates refolding when
normal physiological conditions are restored. (B) In the
presence of chronic stress, which triggers protein
misfolding, re-folding attempts might be particularly
unsuccessful. Under such conditions, the HSP network
can assist in protein unfolding and disaggregation, and
specific targeting of the misfolded or even aggregated
proteins for degradation is usually required. Members of
each HSP family are shown to interact with misfolded
proteins and to reverse the formation of aggregates.
However, whether different HSPs functionally cooperate
with each other in order to modulate mutated protein
toxicity is not yet clear. Solid lines indicate confirmed
actions and interactions; hashed lines refer to those that
are suggested but not fully proven.
D
is
ea
se
 M
od
el
s 
&
 M
ec
ha
ni
sm
s
In parallel to the HSF-1-regulated heat shock response (HSR) in
the cytosol, interconnected pathways in different cellular
compartments also respond to acute cellular stress, including the
unfolded protein response (UPR) in the endoplasmic reticulum and
the mitochondria (Haynes and Ron, 2010; Morimoto, 2011; Walter
and Ron, 2011). Each pathway not only induces the transcriptional
upregulation of genes that enhance refolding capacity, but also the
expression of HSP members that assist in degradation of unfolded
proteins through the proteasome- and lysosome-mediated pathways,
together protecting cells from stress (Parsell and Lindquist, 1993;
Haynes and Ron, 2010; Morimoto, 2011; Walter and Ron, 2011).
HSPs and chronic stress conditions
Protein aggregation hallmarks a high number of chronic diseases
(Balch et al., 2008) that can either be loss-of-function or toxic gain-
of-function disorders. Loss-of-function diseases, including cystic
fibrosis and Gaucher’s disease, are typically caused by recessive
mutations that lead to inefficient folding of the mutated proteins and
their consequent degradation or dysfunction (Fan et al., 1999)
(Fig. 1B). Of note, in recessive diseases, the HSF-1-regulated HSPs
can promote some refolding of (metastable) mutant proteins, thereby
displaying disease-rescuing potential (Yang et al., 2013). In addition,
chaperone inhibition, resulting in less efficient recognition of the
mutant peptides and therefore increasing their degradation, has been
shown to be protective in such diseases (Chanoux and Rubenstein,
2012). Toxic gain-of-function diseases, on the other hand, usually
manifest with the formation of intracellular and/or extracellular
deposits of aggregated proteins, as will be further discussed below
(Chiti and Dobson, 2006; Balch et al., 2008; Morimoto, 2008).
These aggregates are often fundamentally different from those
formed during acute stress because they initially are formed without
being sensed by the (acute) stress responses in the cells. Moreover,
unlike in response to acute stress, in which proteins are unfolded,
proteins in chronic stress are intrinsically misfolded and can
generally not be refolded; these misfolded proteins must be disposed
of (Fig. 1B). This could imply that different HSPs might be crucial
– or rate-limiting – to providing protection in chronic protein-
aggregation diseases than for acute stress. Below, we will focus on
toxic gain-of-function diseases and provide an overview of the
literature on HSPs that could prevent aggregation or/and toxicity of
the disease-associated proteins. Because we aim to identify HSPs
that might be rate-limiting factors for aggregate prevention and thus
targets for intervention in these diseases, we will mainly discuss
effects of HSP overexpression and not include studies on the
downregulation of HSPs. Interestingly, HSP downregulation is often
associated with toxicity and lethality and can result in disease itself.
Therefore, this Review will also provide an overview of aggregation
diseases, known as chaperonopathies, which are caused by
mutations in HSPs. In this way, we aim to recapitulate the role of
HSPs in chronic aggregation diseases from two angles: the
prevention of toxic gain-of-function diseases and their role in
causing disease themselves.
HSPs and proteinopathies
There are numerous human diseases that are associated with the
aggregation of a single dominant peptide or protein. Examples of
such diseases, known as proteinopathies, include polyQ diseases,
PD, ALS and AD. The monogenic forms of neurodegenerative
proteinopathies are rare, and are generally histopathologically
indistinguishable from their corresponding sporadic forms, making
it likely that both forms share a final common pathway. Protein
aggregates are either found inside neurons (e.g. tau tangles in AD)
or outside neurons, in the extracellular space [e.g. amyloid-β (Aβ)
plaques in AD]. Aggregates are generated when proteins become
destabilized, either by mutations changing their native state (e.g.
SOD1 in ALS) or quantity (e.g. α-synuclein in PD), by the
elongation of a certain domain [e.g. huntingtin (Htt) in Huntington’s
disease (HD)] or by domain truncations (e.g. TDP-43 in ALS).
Aggregates range from extremely dense amyloidogenic aggregates
with β-sheet cores (Htt, ataxin-3, Aβ) to more amorphous aggregates
(α-synuclein, SOD1, TDP-43). Although it is still debated whether
the small oligomers or the large inclusions are more toxic, the
overall evidence from model systems strongly suggests that
aggregate prevention generally results in disease amelioration.
Therefore, this Review focuses on aggregate prevention by HSPs
and will reveal that each of these proteinopathies is associated with
a different pattern or ‘barcode’ of rescue depending either on the
HSR or individual HSPs. The elucidation of these barcodes provides
a platform for a rational design of disease-specific therapeutic
strategies. For each disease, we have categorized evidence into four
levels (Fig. 2): in vitro (lowest level), cell studies, non-mammalian
model systems and mammals (highest level). Furthermore, evidence
in Fig. 2 was graded according to the specific effects of each
chaperone: prevention of aggregate formation (black), buffering of
toxic effects caused by diseased protein (gray) and absence of
protective effects (white).
Polyglutamine (polyQ) diseases 
In polyQ diseases, the polyQ tract is elongated beyond a certain
threshold. The transcribed polyQ peptide fragments are thought to
be the initiators of amyloid fibrils and have a strong propensity to
assemble into highly ordered polymers that are extremely rich in β-
sheet structure, thereby creating sodium dodecyl sulfate (SDS)-
insoluble aggregates (Wellington et al., 2000; Chiti and Dobson,
2009). PolyQ expansions in Htt, ataxins and the androgen receptor
have been associated, respectively, with the dominant late-onset
toxic gain-of-function diseases HD, spinocerebellar ataxias (SCA)
and spinal bulbar muscular atrophy (SBMA). All these diseases are
associated with severe motor problems and/or muscle atrophy (Chiti
and Dobson, 2009; Banno et al., 2012; Seidel et al., 2012b). Both
age of onset and protein-aggregation propensity are strongly
associated with the length of the polyQ expansion, further
suggesting that aggregate formation forms the basis of disease
(Gusella and MacDonald, 2000; Wellington et al., 2000).
In cells and non-mammalian model organisms, activation of the
acute HSR pathways has been shown to reduce the extent of polyQ
aggregation. Overexpression of HSF-1 leads to fewer but larger
polyQ aggregates in cells (Pierce et al., 2010). In agreement with
this finding, chemical upregulation of the HSR in cells and non-
mammalian animal organisms reduced a number of dysfunctions
caused by polyQ overexpression (see Fig. 2 for associated
references). Although overexpression of HSF-1 in muscle tissue of
the R6/2 mouse model for HD increased lifespan, there were only
small effects on aggregates (Fujimoto et al., 2005), implying that
effects were compensatory and did not affect the underlying toxic
gain of function. Chemical upregulation of the HSR by the use of
Hsp90/HSPC inhibitors in the R6/2 mouse model leads to transient
beneficial effects, which disappear during disease progression
(Labbadia et al., 2011). Moreover, Hsp90/HSPC inhibition leads
to accelerated degradation of soluble polyQ-Htt, which is
apparently independent of HSR activation; however, this was most
likely due to pleiotropic effects associated with the inhibition of
Hsp90/HSPC instead (Baldo et al., 2012; Yam et al., 2008;
Buchner, 1999).
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Fig. 2. HSP barcodes associate with diverse proteinopathies.
Summary of literature pertaining to the effects on proteinopathies of
activating either the cytosolic heat shock response (HSR/HSF-1), using
HSF-1 activators or HSP90 inhibitors, or overexpressing specific HSPs
from the different families (HSPC, HSPA, HSPD/CCT, DNAJ or HSPB). For
each disease, evidence was categorized into four levels according to the
system or organism in which the effect was examined: in vitro (A), cell
studies (B), non-mammalian model systems (C) and mammals (D).
Evidence was further graded according to the specific effects of the HSP(s)
on the disease: prevention of aggregate formation (black), buffering of toxic
effects caused by diseased protein (gray) and absence of effects (white).
See main text for further explanation. Numbers in the table correspond to
references in the legend. Solid data was cited from review articles, which
are displayed as numbers in the gray column below each disease section.
Data from orginial articles (higher model organisms, subheadings C and D)
are cited in the corrseponding individual cells. reviews, articles with general
information used for the figure; polyQ, polyglutamine diseases; Htt,
huntingtin; SCA, spinocerebellar ataxia; AR, androgen receptor; PD,
Parkinson’s disease; α-syn, α-synuclein; ALS, amyotrophic lateral
sclerosis; AD, Alzheimer’s disease; Aβ, amyloid-β; 990, HSP990; AMCL,
arimoclomol; GA, geldanamycin; CLST, celastrol; GGA,
geranylgeranylacetone; RA, radicicol; A4, drug name (novobiocin analog);
PU, PU-H71. References: (1) Jiang et al., 2012; (2) Gunawardena et al.,
2003; (3) Bauer et al., 2010; (4) Yousuf et al., 2010; (5) McLear et al.,
2003; (6) Hansson et al., 2003; (7) Hay et al., 2004; (8) Tam et al., 2006;
(9) Sontag et al., 2013; (10) Tam et al., 2009; (11) Behrends et al., 2006;
(12) Kakkar et al., 2013; (13) Abisambra et al., 2012; (14) Hageman et al.,
2011; (15) Labbadia et al., 2012; (16) Hageman et al., 2010; (17) our
unpublished results; (18) Peterson and Blagg, 2009; (19) Jana et al., 2000;
(20) Wacker et al., 2004; (21) Perrin et al., 2007; (22) Zourlidou et al.,
2007; (23) Carra and Landry, 2006; (24) Mymrikov et al., 2011; (25)
Boncoraglio et al., 2012; (26) Vos et al., 2010; (27) Tue et al., 2012; (28)
Fujimoto et al., 2005; (29) Pierce et al., 2010; (30) Labbadia et al., 2011;
(31) Neef et al., 2010; (32) Neef et al., 2011; (33) Agrawal et al., 2005; (34)
Sittler et al., 2001; (35) Fujikake et al., 2008; (36) Herbst and Wanker,
2007; (37) Cummings et al., 2001; (38) Chai et al., 1999; (39) Carra et al.,
2010; (40) Rimoldi et al., 2001; (41) Chan et al., 2000; (42) Adachi et al.,
2003; (43) Fliss et al., 1999; (44) Stenoien et al., 1999; (45) Howarth et al.,
2007; (46) Stope et al., 2012; (47) Kondo et al., 2013; (48) Thomas et al.,
2006; (49) Waza et al., 2005; (50) Waza et al., 2006; (51) Almeida et al.,
2011; (52) Rusimini et al., 2011; (53) Katsuno et al., 2005; (54) Malik et al.,
2013; (55) Aridon et al., 2011; (56) Gorbatyuk et al., 2012; (57) Redeker et
al., 2012; (58) Danzer et al., 2011; (59) Auluck et al., 2002; (60) Auluck et
al., 2005; (61) Klucken et al., 2004; (62) Shimshek et al., 2010; (63)
Pemberton et al., 2011; (64) Bruinsma et al., 2011; (65) Outeiro et al.,
2006; (66) Liangliang et al., 2010; (67) Auluck and Bonini, 2002; (68)
Riedel et al., 2010; (69) Song et al., 2013; (70) Gifondorwa et al., 2007;
(71) Gifondorwa et al., 2012; (72) Boillée et al., 2006; (73) Koyama et al.,
2006; (74) Patel et al., 2006; (75) Blumen et al., 2012; (76) Sharp et al.,
2008; (77) Krishnan et al., 2008; (78) Yerbury et al., 2013; (79) Batulan et
al., 2006; (80) Kiaei et al., 2005; (81) Kalmar et al., 2008; (82) Kieran et al.,
2004; (83) Estes et al., 2011; (84) Gregory et al., 2012; (85) Jinwal et al.,
2012; (86) Evans et al., 2006; (87) Tiffany-Castiglioni and Qian, 2012; (88)
Hoshino et al., 2011; (89) Veereshwarayya et al., 2006; (90) Carnini et al.,
2012; (91) Toth et al., 2013; (92) Wilhelmus et al., 2006; (93) Wilhelmus et
al., 2007; (94) Jiang et al., 2013; (95) Pierce et al., 2013; (96) Paris et al.,
2010; (97) van der Putten and Lotz, 2013; (98) Dou et al., 2003; (99)
Miyata et al., 2011; (100) Abisambra et al., 2010; (101) Opattova et al.,
2013; (102) Petrucelli et al., 2004; (103) Dickey et al., 2006; (104)
Sinadinos et al., 2013; (105) Chan et al., 2002; (106) Ansar et al., 2007;
(107) Wang et al., 2008.
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Whereas injection of HSF-1 into an SBMA mouse model resulted
in only small effects in neurons, Hsp90/HSPC inhibition by 17-
AAG, geranylgeranylacetone (GGA) and geldanamycin (GA) not
only substantially increased lifespan, but also diminished aggregates
(Fig. 2). Hsp90s/HSPCs are required for the degradation, regulation,
ligand-binding affinity and stabilization of the androgen receptor, as
well as for its trafficking (Peterson and Blagg, 2009). The strong
effects of Hsp90/HSPC inhibitors on SBMA – but not HD – suggest
that HSF-1 activation and the resulting upregulation of the HSR is
insufficient to modulate polyQ diseases in general. Protective effects
of Hsp90/HSPC inhibitors, if found, are therefore most likely due to
HSF-1-unrelated effects (Baldo et al., 2012).
Upregulation of individual members from HSF-1-regulated HSP
families (e.g. HSPA1A, DNAJB1, HSPB1) was effective in
preventing polyQ aggregation or the associated toxicity in vitro and
in cellular models (Fig. 2). However, in comparative screens
involving larger polyQ expansions, the HSR-regulated HSPs were
usually rather ineffective compared with non-canonical HSPs (Vos
et al., 2010; Hageman et al., 2011; Hageman et al., 2012). Some
effects of Hsp70/HSPA overexpression on polyQ toxicity were
reported in Drosophila melanogaster (Fig. 2). However, these
effects were not associated with aggregate reduction, suggesting that
the observed protection was due to compensatory effects
downstream of aggregate formation; for instance, the loss of normal
PQC functions owing to entrapment of key chaperones, such as
DNAJB1 (Park et al., 2013). Yet, this loss of PQC is apparently not
at the heart of disease in mammals, because restoration of PQC by
HSP70 overexpression did not delay disease progression in the R6/2
HD mouse model (Hansson et al., 2003; Hay et al., 2004). The same
is true for the canonical small HSP HSPB1. Although an earlier
report suggested that HSPB1 overexpression led to a small delay of
Htt toxicity in rats (Perrin et al., 2007), studies in a mouse model for
HD (Zourlidou et al., 2007) as well as several studies in cells
(Fig. 2) showed that HSPB1 is rather inefficient in delaying polyQ
aggregation. Combining these results suggests that HSPB1 might
have some compensatory effects that might initially slightly delay
disease but, because HSPB1 seems not to affect aggregates directly,
this is insufficient to substantially rescue the disease in mammals
(Fig. 2).
In dedicated screens for members of the HSP families that might
be better suppressors of polyQ aggregation, a number of very
effective HSPs were identified, including DNAJB2, DNAJB6,
DNAJB8, HSPB6, HSPB7, HSPB8 and HSPB9. Interestingly, most
of these were not, or were only marginally, regulated by HSF-1 and
were not effective in stimulating substrate refolding after acute stress
(Vos et al., 2010; Hageman et al., 2011; Hageman et al., 2012;
Kakkar et al., 2013). Instead, these HSPs were associated with
degradation of clients through the proteasomal and autophagic
degradation routes. Moreover, whereas DNAJB6, HSPB7 and
HSPB8 delayed aggregation in Drosophila, DNAJB2 was the first
HSP that demonstrated a protective effect on aggregate formation,
functional end points and survival in mice (Labbadia et al., 2012).
Interestingly, our preliminary data regarding transgenic
overexpression of DNAJB6 indicate even larger protective effects
in the R6/2 mice (our unpublished results). The effectiveness of
these non-canonical HSPs in cells, non-mammalian model
organisms and mice might be related to their ability to prevent
initiation of aggregate formation or to assist aggregate clearance
through autophagy, a finding that would be consistent with the
important role that autophagy plays in proteinopathies (Vos et al.,
2010; Boncoraglio et al., 2012; Rubinsztein et al., 2012; Gillis et al.,
2013; Mansson et al., 2013).
In a nutshell, the HSR and individual HSF-1-regulated HSP
members have marginal and mainly compensatory effects in polyQ
diseases. In contrast, other members of the HSP families that can
prevent aggregate initiation or dispose of aggregates might have
potential as targets for therapy in polyQ diseases.
Parkinson’s disease (PD)
About 5-10% of PD cases are monogenic and are caused by either
loss-of-function or toxic gain-of-function mutations. The most
commonly occurring PD-causing mutations are in the mitochondria-
associated genes encoding Parkin (PARK2), PINK1 (PARK6) and
DJ-1 (PARK7) (Lesage and Brice, 2009; Schapira and Tolosa, 2010;
Martin et al., 2011; Klein and Westenberger, 2012). Mutations in
these genes are recessively inherited and usually result in a loss-of-
function effect, mainly impeding mitochondrial function and
turnover. By contrast, a toxic gain-of-function phenotype resulting
in PD is caused by rare dominantly inherited mutations and
multiplications in the genes SNCA (PARK1, PARK4) and LRRK2
(PARK8) (Lesage and Brice, 2009; Schapira and Tolosa, 2010; Klein
and Westenberger, 2012). This Review will focus on these rare toxic
gain-of-function mutations.
Mutations in or multiplications of SNCA lead to increased
oligomerization of the gene product α-synuclein, which is an
intrinsically disordered protein. This enhanced oligomerization
increases the tendency of α-synuclein to form β-sheet structures and
eventually fibrous amyloidogenic inclusions, called Lewy bodies
and Lewy neurites (Lesage and Brice, 2009; Martin et al., 2011;
Roostaee et al., 2013). LRRK2 is a kinase that is involved in the
phosphorylation of α-synuclein. Mutations in LRRK2 are thought to
promote α-synuclein expression, aggregation and toxicity, thereby
increasing the propensity of α-synuclein to self-aggregate (Schapira
and Tolosa, 2010; Martin et al., 2011).
As in polyQ diseases, genetic or chemical activation of HSF-1 can
temporarily compensate for LRRK2 and α-synuclein toxicity in cells
and Drosophila (Fig. 2).
Although individual HSPs such as DNAJA1, DNAJB2, HSPB2/
HSPB3, HSPB6 and HSPB8 inhibited α-synuclein aggregation in
vitro, none of them have proven to be effective in this action in cells
thus far (Fig. 2). HSPB1 and HSPB5 were found to be effective in
preventing α-synuclein aggregation in vitro, in cells and in
Drosophila; however, there is currently no evidence of success in
mouse models. Overexpression of HSPA1 was also shown to be able
to inhibit α-synuclein aggregation in vitro, and decrease α-synuclein
toxicity in cells and in Drosophila. Moreover, HSPA1
overexpression in mice did show some protective effects, although
the data are still disputed (Klucken et al., 2004; Shimshek et al.,
2010) (Fig. 2). As is the case for polyQ diseases, neither
Hsp70/HSPA1 nor any other canonical HSP could prevent aggregate
formation or reduce aggregate size and quantity.
These data taken together would suggest that compensation for
loss of normal PQC by sequestration of HSPs into aggregates plays
a more important role in PD than it does in polyQ diseases. In line
with this notion, a study of α-synuclein in mice showed that
transgenic overexpression of HSPA5 delayed disease onset without
affecting cytosolic protein aggregation. Because HSPA5 is an ER-
resident Hsp70/HSPA and is not expressed in the cytoplasm of the
cell, its mode of action must be indirect. Instead of directly affecting
aggregate formation, HSPA5 most likely compensates for
downstream consequences of aggregation and thereby delays disease
onset (Gorbatyuk et al., 2012).
To conclude, the biophysical nature and intracellular localization
of α-synuclein aggregates are clearly different from aggregates in
425
REVIEW Disease Models & Mechanisms (2014) doi:10.1242/dmm.014563
D
is
ea
se
 M
od
el
s 
&
 M
ec
ha
ni
sm
s
426
polyQ diseases (Ciechanover and Brundin, 2003). Expression of
(mutant) α-synuclein rapidly activates HSF-1, whereas polyQ
expression either does not activate HSF-1 at all, or only transiently
and very late in disease (Ciechanover and Brundin, 2003; Seidel et
al., 2012a). The potential HSP suppressors of PD thus seem to differ
from that of polyQ diseases, thereby resulting in a different HSP
barcode of potential treatment targets (Fig. 2).
Amyotrophic lateral sclerosis (ALS)
About 5% of ALS cases are currently categorized as dominant
monogenic ALS, the most commonly occurring mutations being in
SOD1, TDP-43 and FUS (Andersen and Al-Chalabi, 2011; Al-
Chalabi et al., 2012). Clinically, sporadic and monogenic ALS are
virtually indistinguishable because SOD1- and TDP-43-positive
inclusions are present in both forms of the disease, thereby implying
a final common pathway (Turnder et al., 2013). About 166
mutations in SOD1 have been associated with monogenic ALS.
Although SOD1 mutations were initially thought to cause disease
via a loss of wild-type SOD1 function, SOD1-knockout mice
displayed no phenotype (Saccon et al., 2013). Instead, the
overexpression of mutant SOD1 leads to disease, implying that the
mutant gained a toxic function (Siddique and Deng, 1996; Andersen
and Al-Chalabi, 2011). Mutations in SOD1 indeed structurally
destabilize the protein, thereby increasing its aggregation propensity,
which eventually results in amyloid-fibril formation (Luheshi and
Dobson, 2009). Mutations in TDP-43, an RNA-processing protein
that usually shuttles between the nucleus and cytoplasm of the cell,
render the protein aggregation-prone, which leads to the formation
of dense round or filamentous aggregates in the cytoplasm alongside
stress granules (Luheshi and Dobson, 2009; Andersen and Al-
Chalabi, 2011; Al-Chalabi et al., 2012). Mutations in FUS, another
protein involved in RNA metabolism, also result in large globular
and elongated cytoplasmic inclusions (Andersen and Al-Chalabi,
2011; Al-Chalabi et al., 2012). Nevertheless, FUS-related ALS is
defined as an atypical form because TDP-43-positive aggregates are
not part of the pathology; therefore, this Review will not discuss
FUS-related ALS.
Treatment of Drosophila with the Hsp90/HSPC inhibitor 17-AAG
reduced the characteristic ALS eye-degeneration phenotype in a
TDP-43 model (Gregory et al., 2012). In addition, treatment of the
SOD1-G93A mouse model with 17-AAG not only delayed age of
symptom onset, but also increased lifespan (Kieran et al., 2004;
Kiaei et al., 2005; Kalmar et al., 2008). However, these protective
effects were not reproducible in the SOD1-G37R or the SOD1-
G85R mouse model (Chiti and Dobson, 2009; Gifondorwa et al.,
2012). These contradictory results indicate that protein aggregation
and toxicity mechanisms might depend on the exact kind of
mutation, and therefore result in a different barcode of HSPs for
each SOD1 mutation.
Regarding the effects of individual HSPs on SOD1 aggregation and
toxicity, data in cell lines expressing mutant SOD1 suggest protective
effects of HSPA1, DNAJB1, DNAJB2, HSPB1 and HSPB8 (Fig. 2).
Furthermore, HSPB8 alleviated TDP-43 aggregation and toxicity in
cells and HSPA1A reduced TDP43-associated eye degeneration in
Drosophila (Estes et al., 2011). The intracranial injection of SOD1-
G93A mice with HSPA1 was also protective, whereas long-term
effects of HSPB1 overexpression in mice were absent, although this
awaits further investigation (Gifondorwa et al., 2007; Krishnan et al.,
2008; Sharp et al., 2008; Gifondorwa et al., 2012).
To conclude, except for the aforementioned Hsp90/HSPC
inhibitors, none of the discussed HSPs resulted in long-term rescue
or had direct effects on SOD1 aggregates (Fig. 2). Moreover, it is
not clear whether the effects of the Hsp90/HSPC inhibitors are due
to the elevation of HSF-1-regulated HSPs, or whether they are due
to the broad effects that these inhibitors exert on cell homeostasis.
In summary, the barcode of HSPs that protect against ALS is still
very limited.
Alzheimer’s disease (AD)
The most commonly occurring form of AD is sporadic late-onset
AD. In contrast, only about 1-2% of AD cases occur with early
onset, and these are due to autosomal-dominant mutations in
amyloid precursor protein (APP), presenilin 1 (PSEN1) or presenilin
2 (PSEN2) (Guerreiro et al., 2012). Although intracellular tangles,
consisting of hyperphosphorylated tau and extracellular Aβ plaques,
are present in both sporadic and monogenic AD, it is unclear how
toxicity in AD proceeds. It is disputed as to whether Aβ aggregation
leads to cellular stress and results in tau hyperphosphorylation and
aggregation (described as the amyloid cascade hypothesis), or
whether tau hyperphosphorylation and aggregation precede Aβ
accumulation (described as the tau axis hypothesis) (Götz et al.,
2011). Here, we will provide an unbiased summary of the effects of
HSPs on both Aβ- and tau-related aggregation.
Aβ peptides are the result of APP cleavage via one of two
pathways: a non-amyloidogenic pathway that leads to the generation
of the most common isoform, Aβ40, or an amyloidogenic pathway
that results in the generation of Aβ42 (Guerreiro et al., 2012). AD-
related mutations in APP usually affect the ratio or properties of
these different Aβ species (Guerreiro et al., 2012). Similarly,
mutations in PSEN1 and PSEN2, which are rate-limiting
components of the γ-secretase complex in the amyloidogenic
pathway, result in increased generation of the more fibrillogenic
Aβ42 (Götz et al., 2011; Guerreiro et al., 2012).
HSF-1 injection into an APP rat model increased neuronal health
and reduced Aβ-plaque load (Jiang et al., 2013). Similarly, in
another study, genetic overexpression of HSF-1 in APP mice
diminished soluble Aβ levels (Pierce et al., 2013). In line with these
findings, treatment of APP mice with the HSF-1 activator celastrol
slightly decreased Aβ-plaque load (Paris et al., 2010).
In vitro, it was shown that HSPA1, HSPA5, HSPC1 and
HSPA1/DNAJB1, as well as HSPB1, HSPB5, HSPB6 and HSPB8,
slow down Aβ aggregation when upregulated individually (Fig. 2).
Furthermore, when cells exposed to purified, extracellularly added
Aβ were co-incubated with purified DNAJB1, HSPB1, HSPB5 or
HSPB8, they were protected against Aβ toxicity (Wilhelmus et al.,
2006; Carnini et al., 2012). However, considering that HSPs are
intracellular proteins, whereas Aβ plaques are generally considered
to be extracellular, the relevance of such findings could be debated.
Interestingly, evidence stating that intracellular Aβ aggregation
might precede extracellular plaque formation is accumulating, which
increases the relevance of findings indicating that HSPs are able to
prevent the initiation of aggregation in cells (Hu et al., 2009; Sakono
and Zako, 2010). Although there is no cellular data available at
present, these findings might explain why transgenic overexpression
of HSPA1 and HSPB1 had protective effects in mouse models for
Aβ (Hoshino et al., 2011; Tóth et al., 2013). However, it is
questionable whether Aβ aggregation was directly affected by
HSPA1 overexpression in transgenic mice, or whether the observed
protective effects were due to more general compensatory effects of
HSPA1 (Hoshino et al., 2011).
Another protein that has been associated with neuronal death in AD
is tau. Tau is an unstructured and dynamic protein that is normally
involved in stabilization of microtubules, but becomes
hyperphosphorylated and detaches from microtubules under
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conditions of stress. This detachment results in microtubular collapse
and in the aggregation of tau into well-ordered and periodic protein
deposits (Götz et al., 2011; Mandelkow and Mandelkow, 2012).
In cells, the HSF-1 activator HSF1A reduced tau aggregation by
increasing proteasomal degradation of tau (Opattova et al., 2013).
Likewise, Hsp90/HSPC-directed drugs, such as geldanamycin,
enhanced clearance of tau from cells, thereby reducing its toxicity
(Fig. 2). Moreover, the HSF-1 activator radicicol and the GA
derivative 17-AAG alleviated tau toxicity in Drosophila larvae
(Fig. 2).
Multiple HSPs alleviated tau toxicity in cells, including HSPA8,
HSPA1, Hsp90s/HSPC, DNAJA1 and HSPB1 (Fig. 2). In addition,
HSPB1 rescued behavioral defects in a mouse model for tauopathy
(Abisambra et al., 2010). However, there have been no studies to
investigate the role of the other HSPs in mammals to date.
To conclude, interpreting the data about the effects of HSPs on
AD needs to be done with great caution for two main reasons.
Firstly, it is not yet known whether AD is initiated by intracellular
(tau or Aβ) or extracellular (Aβ) aggregates. Secondly, although
extracellularly added or leaked HSPs might affect toxicity of Aβ
plaques, it is still unclear how intracellular overexpression of HSPs
can have direct effects on toxicity in AD. These factors currently
limit elucidation of the barcode of HSPs for AD.
Different aggregation diseases have a different HSP barcode
Although all diseases discussed here are toxic gain-of-function
aggregation diseases, the barcode of HSPs with protective potential
clearly differs depending on the disease (Fig. 2). This variability
strongly suggests that the neurodegenerative proteinopathies
discussed in this Review are biochemically and biologically distinct.
Because all proteinopathies presumably impede on overall protein
homeostasis, simply rescuing the overall folding capacity by
activation of the complete (acute) HSR (Fig. 1A), or expression of
individual components thereof, might lead to some protective
effects. However, these effects are generally small and transient, and
do not actually affect aggregate formation of the specific diseased
proteins themselves. Instead, the effects of the HSR might
compensate for entrapment of chaperones and/or other components
into aggregates (e.g. certain crucial transcription factors). The
underlying toxicity of the aggregates themselves is likely to go
beyond these effects on protein homeostasis and will furthermore
directly impair other functions, such as axonal transport, organelle
dynamics (physical obstruction or cytoskeletal collapse) and
membrane integrity. Assuming that aggregation indeed is the reason
for toxicity in all these diseases, each proteinopathy requires specific
HSPs that either directly prevent aggregation or that recognize early
aggregate intermediates and target these for degradation. These
HSPs are likely to be found among the ‘non-canonical HSPs’, many
of which have not yet been fully explored for each of these diseases.
Chaperonopathy: the case of ‘sick’ HSPs
So far, we have highlighted how HSPs might act as a first line of
defense in preventing proteinopathies. Sometimes, however, HSPs
themselves are mutated, leading to pathological conditions termed
chaperonopathies (Macario and Conway de Macario, 2002;
Macario et al., 2005; Macario and Conway de Macario, 2007).
Although the term ‘chaperonopathy’ was initially used to include
any condition associated with putative alteration in the expression,
post-translational modification or localization of chaperones, this
Review will only discuss those diseases in which genetically
inherited mutations in the HSPs are the direct causative factor
(Table 1).
Members of the HSPB, DNAJ and chaperonin families as well as
some chaperone cofactors have been implicated in the genetic
chaperonopathies described so far (Table 1). No genetic
chaperonopathies are associated with the Hsp70/HSPA or
Hsp90/HSPC family members, either because of functional
redundancy within these families or because they are crucial to the
central chaperone machinery such that mutations leading to
functional defects are incompatible with life.
Clinically, genetic chaperonopathies can be categorized into
neuropathies [hereditary spastic paraplegia, motor neuropathy, distal
hereditary motor neuropathy (dHMN)], myopathies (dilated
cardiomyopathy, leukodystrophy, desmin-related myopathy,
mitochondrial myopathy, muscular dystrophy) or retina- and eye-
lens-related diseases (congenital cataracts) (Macario et al., 2005).
Although some chaperonopathies are recessive (and thus probably
related to loss of function of the chaperone), most were found to be
dominant, as is especially the case for the HSPBs (Table 1). We have
labeled or ‘barcoded’ these HSP-associated chaperonopathies
depending on the type of disease and mode of inheritance (Fig. 3).
Hsp60/HSPD- and TRiC/CCT-related chaperonopathies
A mutation in the Hsp60/HSPD chaperone system has been linked
to an autosomal-dominant disease known as hereditary spastic
paraplegia 13 (SPG13). The disease is characterized by spasticity of
lower limbs due to massive degeneration of distal ends of long
axons in the spinal cord. The mutation leads to reduced chaperonin
activity, which has been attributed to haploid insufficiency due to
incorporation of functionally deficient Hsp60/HSPD subunits (Bross
et al., 2008; Hansen et al., 2002). Another chaperonopathy involving
Hsp60/HSPD is the recessive mitCHAP-60 disease, associated with
psychomotor developmental delay, in which mutations lead to
entropic destabilization of the Hsp60/HSPD oligomer and cause its
premature disassembly. This renders Hsp60/HSPD incapable of
fulfilling its normal function, resulting in disease (Parnas et al.,
2009).
The Hsp60/HSPD complex resides in mitochondria; however, a
comparable eukaryotic chaperonin system known as TRiC (also
known as CCT) is present in the cytosol and is mainly involved in
tubulin and actin folding. Mutations in TRiC subunits might affect
its complex formation and thereby its ability to bind and fold tubulin
and actin. Because cytoskeletal integrity is crucial in axonal
transport, this might explain why such mutants primarily affect
functionality of long axons, thus leading to sensory neuropathies
(Lee et al., 2003).
DNAJ-related chaperonopathies
There are four recessive chaperonopathies associated with members
of the DNAJ family (Table 1). The first one involves a DNAJB2
splice mutation that causes dHMN, characterized by muscle
weakness of the extremities as a consequence of progressive
degeneration of motor neurons in the spinal cord (Blumen et al.,
2012). DNAJB2 has several clients and possesses degradation-
related functions (Chapple et al., 2004; Westhoff et al., 2005). The
DNAJB2 mutant is unable to handle its natural clients, which
therefore eventually aggregate and form intracellular inclusions
(Blumen et al., 2012).
The second recessive disease caused by mutations in a member
of the DNAJ family involves DNAJC29. Mutations in DNAJC29
lead to cerebellar ataxia with peripheral neuropathy, which is
referred to as ARSACS. The disease is characterized by dysarthria,
distal muscle wasting, foot deformities and truncal ataxia,
including the absence of sensory evoked potentials in the lower
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limbs (Bouchard et al., 1998). Although the normal function of
DNAJC29 is not well understood, roles in mitochondrial dynamics
and in recruitment of HSPA for the mediation of ataxin-1
degradation have been suggested (Parfitt et al., 2009; Girard et al.,
2012). In line with this, a recently identified ARSACS-causing
mutation (T3702A) resides in the ubiquitin-binding domain of this
protein (Gregianin et al., 2013). However, mutations outside this
domain can also lead to disease, so the loss-of-function mechanism
remains unclear.
Mutations in DNAJC19 have been identified to cause an
autosomal-recessive cardiomyopathy (Davey et al., 2006; Ojala et
al., 2012). DNAJC19 normally plays a crucial role in mitochondrial
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Table 1. Chaperonopathies 
Family Mutation Inheritance Disease 
Chaperone-mediated 
rescue References 
Hsp60/HSPD   
SPG13 
 
V72I in SPG13; 
chromosome 2q33.1; 
c.292G > A/p.V98I 
Dominant Hereditary spastic paraplegia NV Bross et al., 2008;  
Hansen et al., 2002 
mitHSP60 D29G Recessive Hypomyelinating leukodystrophies 
(HMLs); MitCHAP-60 disease 
NV Magen et al., 2008 
CCT/TRiC   
CCT/MKKS 
 
20p12 in MKKS gene; 
H84Y, A242S 
Recessive McKusick-Kaufman syndrome (MKS) NV Stone et al., 2000 
CCT/MKKS 
 
MKKS locus BBS6,  
BBS10, BBS12 
Recessive Bardet- Biedel Syndrome (BBS) 
 
NV Stone et al., 2000;  
Katsanis et al., 2000; 
Slavotinek et al., 2000; 
Stoetzel et al., 2007 
CCT delta/MKKS 
 
C450Y in CCT delta Recessive Hereditary sensory neuropathy  
(HSN); Charcot-Marie-Tooth  
(CMT); hereditary motor and 
sensory neuropathy (HMSN) 
NV Lee et al., 2003 
Hsp40/DNAJ   
DNAJB2 (HSJ1) Splice mutation in HSJ1 
gene 
Recessive Distal hereditary motor neuropathy 
(dHMN) 
NV Blumen et al., 2012 
DNAJB6 F93L, F89I, P96R Dominant Limb-girdle muscular dystrophy type 
1D (LGMD1D) 
NV Sarparanta et al., 2012; 
Harms et al., 2012 
DNAJC5 c.346_348 delCTC, 
c.344T>G; pLeu116del, 
pLeu115Arg 
Dominant Autosomal-dominant adult-onset 
neuronal ceroid lipofuscinoisis 
(ANCL; also known as Kufs  
disease) 
NV Noskova et al., 2011; 
Velinov et al., 2012; 
Cadieux-Dion et al., 2013 
DNAJC6 p.Q734X; c.801-2 A>G Recessive Juvenile Parkinsonism NV Edvardson et al., 2012; 
Körolu et al., 2013 
DNAJC19 IVS3-1GRC; c.300delA Recessive Dilated cardiomyopathy with ataxia 
(DCMA) 
NV Davey et al., 2006;  
Ojala et al., 2012 
DNAJC29 c.3484 G>T, p.E1162X;  
c.11,707C>T, p.R 3903X  
in SACS; T3702A 
Recessive Spastic ataxia of Charlevoix- 
Saguenay (ARSACS) 
NV Bouchard et al., 1998; 
Engert et al., 2000; 
Bouhlal et al., 2011; 
Gregianin et al., 2013 
Small Hsp/HSPB   
HspB1 P39L, G34R, E41K,  
G84R, L99M, R127W, 
S135F, R136W, R140G, 
K141Q, T151I, S156Y, 
T164A, T180I, P182L, 
R188W, 476_477delCT, 
pGln175X 
Dominant; 
recessive (L99M) 
Williams syndrome; Charcot-Marie-
Tooth disease 2 (CMT2); distal 
hereditary motor neuropathy 
(dHMN) 
 
HspB-mediated 
rescue for P182L 
mutation* 
*(Carra et al., 2010); 
Boncoraglio et al., 2012; 
Datskevich et al., 2012 
HspB3 R7S Recessive Motor neuropathy (MN) NV Kolb et al., 2010 
HspB4 W9X, R12C, R21L, R49C, 
R54C, F71L, G98R, 
R116C 
Dominant; 
recessive 
(W9X) 
Autosomal-dominant congenital 
cataract (ADCC) 
 
NV Boncoraglio et al., 2012 
HspB5 R11H, P20S, 450delA, 
R69C, D109H, D140N, 
A171T, R56W, 
c.343delT, R120G, 
Q151X, G154S, R157H, 
464delCT 
Dominant; 
recessive 
(R56W) 
Congenital cataract; myofibrillar 
myopathy; dilated cardiomyopathy; 
desmin-related myopathy 
 
HSPB1-, BAG3-, 
HSPB8-mediated 
rescue** 
Boncoraglio et al., 2012; 
**(Zhang et al., 2010; 
Hishiya et al., 2011;  
Raju and Abraham, 
2013) 
HspB8 K141E, K141N, K141T Dominant 
 
Distal hereditary motor neuropathy 
(dHMN); Charcot-Marie-Tooth 
disease 2 (CMT2) 
NV Irobi et al., 2004; Tang et 
al., 2005; Nakhro et al., 
2013 
NV, not verified. 
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import (Mokranjac et al., 2003), implying that mitochondrial defects
underlie the disease.
More recently, mutations in DNAJC6 were found to be
associated with juvenile-onset Parkinsonism (Edvardson et al.,
2012; Köroğlu et al., 2013). DNAJC6 (also known as auxilin) is a
neuron-specific protein that assists Hsc70/HSPA8 in mediating
clathrin-coated-vesicle disassembly and thus plays a role in
synaptic-vesicle recycling (Ungewickell et al., 1995; Xing et al.,
2010). Mutations in DNAJC6 are predicted to lead to a truncated
version of the protein, which fails to support Hsc70/HSPA8 in its
normal function.
In addition to these recessive diseases, two DNAJ-related
chaperonopathies are dominantly inherited (Table 1) and could cause
disease either through haploinsufficiency, by dominant-negative
effects or via a toxic gain of function. Mutations in DNAJB6, all of
which map to a glycine-phenylalanine-rich region, are associated
with limb-girdle muscular dystrophy type 1D (LGMD1D). The
molecular mechanism underlying the disease has been suggested to
involve loss of function resulting in protein accumulations and
autophagic pathology in muscle fibers (Harms et al., 2012;
Sarparanta et al., 2012). This reduced chaperone function might be
due to haploinsufficiency but, because DNAJB6 is present in cells
as polydispersed complexes, mutants might also exert dominant-
negative effects on the wild-type protein.
Mutations in DNAJC5 cause an autosomal-dominant
neurodegenerative disease, named Kufs disease or adult-onset
neuronal ceroid lipofuscinosis. Clinical symptoms include dementia,
ataxia and speech impairments that worsen over time. Normally,
DNAJC5 is found in synaptic vesicles, where it is involved in
polymerization of dynamin (Zhang et al., 2012). Dysfunction of
DNAJC5 owing to mutations at a crucial lysine position leads to its
reduced palmitoylation and hence abnormal sorting and localization
of DNAJC5, which colocalized ER and Golgi markers (Nosková et
al., 2011). This leads to decreased levels of DNAJC5 in the brain of
diseased individuals, meaning that the disease is most likely caused
by haploinsufficiency.
HSPB-related chaperonopathies
Mutations in several members of the HSPB family, irrespective of
the member involved, are found in highly conserved amino acid
residues or in the α-crystallin domain, which is a characteristic
feature of this family of HSPs (Boncoraglio et al., 2012). The α-
crystallin domain is required for intra/intermolecular interactions
and the stabilization of homo- and hetero-oligomer formations of the
HSPB members. Because HSPBs are highly expressed in muscles
and have a role in cytoskeleton stability (Tessier et al., 2003;
Kampinga and Garrido, 2012), mutations usually affect cellular
axonal transport (neurological and sensory disorders) and contractile
functions (muscular disorders).
The presence of many of the dominant HSPB mutants in protein
aggregates implies that they might have acquired a toxic gain of
function similar to the proteins in proteinopathies (Fig. 2). There
is indeed biochemical evidence that some mutants, such as the
P182L mutant of HSPB1 (Ackerley et al., 2006), R49C and R116C
of HSPB4 (Andley et al., 2002; Mackay et al., 2003), and R120G,
Q151X and 464delCt of HSPB5 (Bova et al., 1999; Perng et al.,
2004; Hayes et al., 2008) are intrinsically unstable and might thus
cause disease by forming aggregates (toxic gain of function).
However, it must be noted that the presence of HSPBs in
aggregates could also be due to a loss of function, reflecting their
failed attempt to handle a client with which they subsequently co-
aggregate.
Evidence for haploinsufficiency, at least for HSPB1 mutations, is
suggested by findings implying that reduced levels of HSPB1 lead
to damage in sensory and motor neurons that can be rescued by
ectopic expression of HSPB1 (Lewis et al., 1999; Boncoraglio et al.,
2012). Partial evidence for haploinsufficiency has also been
provided for HSPB8 mutants, which have lost the HSPB8
chaperone-like activity to deal with aggregation-prone polyQ
proteins, resulting in Charcot-Marie-Tooth disease (Carra et al.,
2008).
Moreover, considering that HSPBs are known to form oligomers
with other members of the same family, it is possible that HSPB
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Family Members Neuropathy Myopathy Retina-related disease 
h-SP dHMN MN CMT2 DCM MFM LD MD CC DT
Hsp90/HSPC
Hsp70/HSPA
Hsp60/HSPD SPG13
mitHsp60
CCT/TriC gamma
CCT/Tric
delta
Hsp40/DNAJ DNAJB2
DNAJB6
DNAJC5
DNAJC19
DNAJC29
Small Hsp/HSPB     HSPB1
HSPB3
HSPB4
HSPB5
HSPB8
Fig. 3. Overview of chaperonopathies caused by mutations in HSPs. Mutations that lead to either recessive (white boxes) or dominant (black boxes)
chaperonopathies have been described for six ‘families’ of HSP. Each chaperonopathy is categorized as a neuropathy, myopathy or retina-related disease
(cataracts). The mutations in HSPs involved in both recessive and dominant diseases have been shaded gray. h-SP, hereditary-spastic paraplegia; dHMN,
distal hereditary motor neuropathy; MN, motor neuropathy; CMT2, Charcot-Marie-Tooth disease 2; DCM, dilated cardiomyopathy; MFM, myofibrillar myopathy;
LD, leukodystrophy; MD, muscular dystrophy; CC, congenital cataract; DT, dystrophy.
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mutants could affect the function of other HSPBs via dominant-
negative effects. For example, HSPB8 mutants have an abnormally
high affinity for endogenous HSPB1, thus potentially impairing
HSPB1 or HSPB1-HSPB8 complex function (Irobi et al., 2004).
Similarly, certain HSPB1 mutants affect endogenous HSPB8,
leading to loss of HSPB8-HSPB1 complex formation (Fontaine et
al., 2006). Furthermore, abnormal interaction of the R116C-HSPB4
mutant with HSPB5 and HSPB1 has been reported (Fu and Liang,
2002; Fu and Liang, 2003).
Therefore, not only a toxic gain of function (aggregation) might
be responsible for HSPB-related chaperonopathies, but also a loss
of function, which could either be direct, due to the mutation, or
indirect, due to sequestration of wild-type HSPBs by the mutated
HSPB forms. In addition, alteration of HSPB oligomerization
properties and interactions with other HSPB members and/or
haploinsufficiency might play a role in HSPB-related
chaperonopathies.
Chaperone intervention to rescue chaperonopathies
Different HSPs have a role in anti-aggregation of various
proteinopathies (Fig. 2). However, whether other HSPs might be
able to rescue chaperonopathies has been scarcely studied. A few
reports suggest that this could indeed be possible. Firstly,
aggregation caused by some HSPB5 mutants is prevented by
overexpression of wild-type HSPB1 (Zhang et al., 2010; Raju and
Abraham, 2013), BAG3 (Hishiya et al., 2011) and wild-type HSPB8
(Chávez Zobel et al., 2003). Secondly, aggregation associated with
the expression of the P182L-HSPB1 mutant in cell models was
significantly reduced by the overexpression of wild-type HSPB8
(Carra et al., 2010). Whether such rescues are due to prevention of
the formation of toxic aggregates containing mutant HSPB or
whether they reflect compensation of loss of HSPB functions
remains to be elucidated.
Conclusions and future perspectives
The existence of different ‘barcodes’ for the rescue of specific
aggregation diseases suggests that, although loss of protein
homeostasis with aging might contribute to disease initiation (e.g.
by HSF-1 abrogation, restoring general protein homeostasis or
components thereof), boosting HSF-1 activity is usually insufficient
for long-term protection in most dominantly inherited
proteinopathies. Chronic expression of these aggregation-prone
proteins in fact often does not trigger activation of the HSR until late
in disease. By then, aggregates might have already sequestered
chaperones and thereby disturbed normal protein homeostasis,
resulting in cell death. In earlier stages of disease, protein aggregates
could already affect neuronal and muscular cell function (even
without causing cell death) by altering functions such as axonal
transport, organelle dynamics and plasma-membrane-receptor
function, without directly impairing protein homeostasis. It has been
shown in several mouse models for HD that reversible functional
impairments precede neuronal cell loss (Yamamoto et al., 2000).
However, in cellular and simple animal models, such functional
defects could be missed, and cell-death-related effects (including
disturbances in protein homeostasis) might prevail, which would
explain the observed rescue by the activation of the HSR or by the
overexpression of its individual components. However, these HSR-
related effects usually do not coincide with aggregate prevention and
therefore do not lead to significant long-term effects in mammalian
animal models.
The human genome encodes many HSP members that are not
regulated by the acute HSR. Although not yet studied intensively,
our review clearly shows that some of these ‘non-canonical’
members can specifically rescue aggregation caused by the distinct
proteinopathies, some of which have now also been demonstrated
to be effective in mouse models. Interestingly, several of these
non-canonical HSPs also cause chaperonopathies if mutated
(DNAJB2, DNAJB6, HSPB8). This not only indicates that these
HSPs have essential PQC functions, but also suggests that their
effects on proteinopathies might not be an artifact of their
overexpression, but rather reflect an augmentation of their natural
function.
A potential worry in all HSP-overexpression or -boosting studies
is that it leads to network adaptations (which would annihilate long-
term effectiveness) or to multiple side effects, including
enhancement of carcinogenesis, as was demonstrated for the
manipulation of HSF-1 activity (Mendillo et al., 2012). Although
network adaptations are to be expected upon manipulation of the
driving forces of chaperone machinery (e.g. Hsp90/HSPC or
Hsp70/HSPA), such effects might be less likely for those
components that only steer the specificity of these machines (e.g.
HSPBs or DNAJs). Although we found no evidence for effects of
DNAJB6 on the chaperone network (our unpublished results), it
remains important to further investigate whether long-term
overexpression of DNAJB6 or other proteinopathy-rescuing HSPs
might have side effects.
Finally, only limited comparative data on the potential rescue of
the non-HSR-regulated HSPs and the various proteinopathies or
chaperonopathies are available. There still might be many currently
unknown suppressors of specific diseases to be uncovered, which
would further barcode these diseases. This would not only help to
pinpoint therapeutic targets for intervention, but would also help
with understanding differences and similarities between the toxic
mechanisms underlying the various proteinopathies.
This article is part of a review series on protein-folding diseases. See related
articles at http://dmm.biologists.org/site/protein-folding-disease.xhtml.
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